All NewsBio/Pharma News
All PublicationsPharmTechPharmTech Europe
MarketplaceICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksWhitepapers
Webcasts
All VideosAsk the ExpertBehind The HeadlinesBuy, Sell, HoldDrug Digest VideosDrug Solutions PodcastPeer ExchangeSexy ScienceTech Talk
Conference CoverageConference ListingEvents
Subscribe
AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
Spotlight -
  • Analytics
  • Dosage Forms
  • Drug Development
  • Manufacturing
  • Outsourcing
  • Quality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Webcasts
    • Subscribe
Advertisement

Behind the Headlines Episode 14–Investment Trends, Policy Realignments, and Vaccines

April 2, 2025
By Chris Spivey
News
Video

Christian Cobaugh, Eswar Iyer, and Vincenzo Antignani go behind the headlines to discuss a mixture of investment trends, policy realignments, trade and stock recalibrations, and an apparent crusade against vaccines both new and old.

Video Player is loading.
Current Time 0:00
/
Duration 0:00
Loaded: 0%
0:00
Stream Type LIVE
Remaining Time -0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions settings, opens captions settings dialog
    • captions off, selected

      This is a modal window.

      Beginning of dialog window. Escape will cancel and close the window.

      Text
      Background
      Window
      Font Size
      Text Edge Style
      Font Family

      End of dialog window.

      This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

      Behind the Headlines is a bi-weekly panel discussion examining the latest trends, readouts, and other factors that drive pharmaceutical news and innovation. Each episode features consultants, venture capitalists, scientists, patient advocates, and journalists discussing the prior weeks’ top news while seeking to highlight the more enduring lessons that hide behind the headlines.

      In episode 14, panelists Christian Cobaugh, PhD, CSO and founder of Vernal Biosciences; Eswar Iyer, PhD, co-founder and CSO, Aikium Inc., and Vincenzo Antignani, PhD, Technical training lead, Asahi Kasei Bioprocess America, Inc., adjunct facility Northeastern University & Governing Committee (GC) Member, NIIMBL | The National Institute for Innovation in Manufacturing Biopharmaceuticals, discuss a mixture of investment trends, policy realignments, trade and stock recalibrations, and an apparent crusade against vaccines both new and old.

      Performance advances in both China and India have led to renewed investments from other countries into both infrastructure and licensing agreements. Novo Nordisk has bought into the “triple G” idea, gaining a GLP-1/GIP/glucagon triple agonist from China’s United Laboratories for up to $2 billion (1). In addition, AstraZeneca is committing up to $11 billion to Chinese Collaborations including a Beijing R&D Hub (2).

      Changing skills requirements for future workforce in a time of turmoil was a major consideration for the panel, appearing and reappearing throughout the conversation. It included the re-folding of recently fired National Institutes of Health workers, as Robert F. Kennedy, Jr. pursues his plans to slash the Department of Health and Human Services’ workforce by 25%, implement massive reorganization, and consolidate authorities, creating a new agency for a ‘Healthy America’ (3).

      Conversation also turned to attitudes toward messenger RNA, as the United States outlines plans to end vaccine funds for poor countries, in parallel to several other efforts to frame vaccines as just-one-choice-among-many-options, to discuss with one’s healthcare provider (4).

      Lastly, 23andMe’s future in bankruptcy protection after having held, at its highest, a market valuation of $6 billion dollars, was bruited about. The panel also examined the company’s chances of legally selling customer genomic data as a lift raft, and also, what the demise of such a pioneering company means in the overall commercial landscape at this time.

      Click the video above to watch the discussion.

      References

      1. Sunny, M. Novo Bets on 'Triple G' Obesity Drug in up to $2 billion Deal with Chinese Biotech. Reuters. March 24, 2025, https://finance.yahoo.com/news/novo-licenses-chinese-biotechs-obesity-102141800.html

      2. Philippidis, A. AstraZeneza Commits Up to $11B+ to Chinese Collaborations, Beijing R&D Hub, Genetic Engineering and Biotechnology News, March 21, 2025. https://www.genengnews.com/topics/drug-discovery/astrazeneza-commits-up-to-11b-to-chinese-collaborations-beijing-rd-hub

      3 Owermohle, S.; Lawrence, L.; and Bannow, T. RFK Jr. Plans to Slash HHS Workforce by 25% in Massive Reorganization. Stat News. March 27, 2025, https://www.statnews.com/2025/03/27/rfk-jr-10000-job-cuts-hhs-restructuring-health-agency-impacts-cdc-fdaG-nih-cms

      4Kirchgaessner, S.; Glenza, J. Trump Administration at ‘War’ with mRNA Technology: Scientists Alarmed Vaccine Skeptics Could Kill Research. The Guardian. March 27, 2025. https://www.theguardian.com/us-news/2025/mar/27/trump-vaccine-skeptics-research-funding

      5. Satija, B.; Shah, A.; Misra, S. DNA Testing Firm 23andMe Files for Bankruptcy as Demand Dries Up. Reuters, March 25, 2025. https://www.reuters.com/business/healthcare-pharmaceuticals/dna-testing-firm-23andme-files-chapter-11-bankruptcy-sell-itself-2025-03-24/

      Recent Videos
      Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
      Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
      DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
      Key Leaders at BIO 2025 Respond to Continuing Political Shifts
      Ask the Expert: Adventitious Contamination Control
      Ask the Expert: Adventitious Contamination Control
      Behind the Headlines, Episode 19: CGT Cost Pressures, BioNTech’s CureVac Move, and Spain’s CAR-T Model
      Behind the Headlines, Episode 19: CGT Cost Pressures, BioNTech’s CureVac Move, and Spain’s CAR-T Model
      BIO 2025: Pulmonary Drug Delivery
      BIO 2025: Pulmonary Drug Delivery
      Behind the Headlines, Episode 18
      Behind the Headlines, Episode 18: Sanofi, GSK Go Big in M&A, mRNA Momentum Falters, and More
      A CDMO’s Role in API Quality
      A CDMO’s Role in API Quality
      CPHI Americas 2025: The Evolving Role of the CDMO
      CPHI Americas 2025: The Evolving Role of the CDMO
      Drug Digest: Patient Preference Drives Solid Dosage Trends
      Drug Digest: Patient Preference Drives Solid Dosage Trends
      Ask the Expert: Quality Control Units
      Ask the Expert: Quality Control Units
      Related Content
      Advertisement

      Thornhill, Ontario, Canada - October 31, 2020: LEO Pharma Canada sign outside their head office building in Thornhill, Ontario, Canada. LEO Pharma AS is a multinational Danish pharmaceutical company | Image Credit: © JHVEPhoto - stock.adobe.com.

      LEO Pharma Takes Over Global Development of Spevigo for Rare Skin Disease GPP

      Christopher Cole
      July 14th 2025
      Article

      The IL-36 inhibitor is being explored for additional inflammatory skin conditions, aiming to expand treatment options for underserved patient groups.


      Drug Solutions Podcast: Growth and Advancements in Fill/Finish

      Drug Solutions Podcast: Growth and Advancements in Fill/Finish

      Felicity Thomas
      June 25th 2024
      Podcast

      In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.


      Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

      EMA Moves to Secure Supply of Critical Drugs Used During Pregnancy

      Susan Haigney
      July 10th 2025
      Article

      The agency’s Executive Steering Group on Shortages and Safety of Medicinal Products has issued recommendations to address vulnerabilities in the supply chain of anti-D immunoglobulins.


      Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

      Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

      Felicity Thomas
      May 28th 2024
      Podcast

      In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.


      Pharmaceutical research and development in laboratory, with focus on medicine preparation, powder substances, and glass vials for drug formulation and testing | Image Credit: © felix_brönnimann - stock.adobe.com

      Dosage Form Compounding in the Workplace Environment

      Paul L. Pluta;Alan M. Mancini;Nishant B. Thakar;Varanya Chaiyaperm
      July 8th 2025
      Article

      An ordered pharmaceutical compounding process for use in 503A pharmacies, 503B outsourcing facilities, pharmaceutical industry, and other applications.


      Bone structure 3d illustration, normal and with osteoporosis | Image Credit: © adimas - stock.adobe.com

      Theramex Treatment for Osteoporosis in Postmenopausal Women Accepted by Scottish Medicines Consortium

      Patrick Lavery
      July 7th 2025
      Article

      The company estimated that more than 1000 women in Scotland at very high risk of fracture would be eligible for treatment.

      Related Content
      PharmTech News
      |
      Behind the Headlines
      |
      Quality Systems
      |
      Manufacturing
      Advertisement

      Thornhill, Ontario, Canada - October 31, 2020: LEO Pharma Canada sign outside their head office building in Thornhill, Ontario, Canada. LEO Pharma AS is a multinational Danish pharmaceutical company | Image Credit: © JHVEPhoto - stock.adobe.com.

      LEO Pharma Takes Over Global Development of Spevigo for Rare Skin Disease GPP

      Christopher Cole
      July 14th 2025
      Article

      The IL-36 inhibitor is being explored for additional inflammatory skin conditions, aiming to expand treatment options for underserved patient groups.


      Drug Solutions Podcast: Growth and Advancements in Fill/Finish

      Drug Solutions Podcast: Growth and Advancements in Fill/Finish

      Felicity Thomas
      June 25th 2024
      Podcast

      In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.


      Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

      EMA Moves to Secure Supply of Critical Drugs Used During Pregnancy

      Susan Haigney
      July 10th 2025
      Article

      The agency’s Executive Steering Group on Shortages and Safety of Medicinal Products has issued recommendations to address vulnerabilities in the supply chain of anti-D immunoglobulins.


      Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

      Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

      Felicity Thomas
      May 28th 2024
      Podcast

      In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.


      Pharmaceutical research and development in laboratory, with focus on medicine preparation, powder substances, and glass vials for drug formulation and testing | Image Credit: © felix_brönnimann - stock.adobe.com

      Dosage Form Compounding in the Workplace Environment

      Paul L. Pluta;Alan M. Mancini;Nishant B. Thakar;Varanya Chaiyaperm
      July 8th 2025
      Article

      An ordered pharmaceutical compounding process for use in 503A pharmacies, 503B outsourcing facilities, pharmaceutical industry, and other applications.


      Bone structure 3d illustration, normal and with osteoporosis | Image Credit: © adimas - stock.adobe.com

      Theramex Treatment for Osteoporosis in Postmenopausal Women Accepted by Scottish Medicines Consortium

      Patrick Lavery
      July 7th 2025
      Article

      The company estimated that more than 1000 women in Scotland at very high risk of fracture would be eligible for treatment.

      Advertisement
      Advertisement
      Advertisement
      x
      About Us
      Advertise
      Contact Us
      Editorial Info
      Editorial Advisory Board
      Do Not Sell My Personal Information
      Privacy Policy
      Terms and Conditions
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.